Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain RARE message board posts where the ticker symbol RARE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest RARE SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001564590-17-023875 (34 Act)  Size: 535 KB
2017-11-15 001-36276
171205083
8-K  Documents Current report, items 2.01 and 9.01
Acc-no: 0001193125-17-335163 (34 Act)  Size: 43 KB
2017-11-07 001-36276
171181990
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-17-335126 (33 Act)  Size: 651 KB
2017-11-07 333-221381
171181288
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-17-335103 Size: 51 KB
2017-11-07
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-17-021336 (34 Act)  Size: 4 MB
2017-11-03 001-36276
171174211
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-17-021270 (34 Act)  Size: 661 KB
2017-11-02 001-36276
171173200
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-17-320293 Size: 43 KB
2017-10-26
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-17-316200 Size: 33 KB
2017-10-23
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-17-311410 Size: 32 KB
2017-10-17
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-17-308920 Size: 30 KB
2017-10-12
More RARE SEC Filings


Related news from
Fri, 08 Dec 2017
13:04:25 +0000
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Mon, 04 Dec 2017
21:06:20 +0000
Does This Rare-Disease Biotech Have A Winner On Its Hands?
Ultragenyx popped to a seven-week high Monday on data from a Phase 3 trial for a drug to treat a rare bone disease.
Mon, 04 Dec 2017
14:29:00 +0000
Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Mon, 04 Dec 2017
12:53:10 +0000
Ultragenyx shares rise 4% on late-stage results for rare disease therapy
Ultragenyx Pharmaceutical Inc. shares rose 4.4% in premarket trade Monday after the company said that the rare disease therapy it is developing with Kyowa Hakko Kirin Co. Ltd. had positive results in a ...
Mon, 04 Dec 2017
12:30:00 +0000
Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
NOVATO, Calif. and TOKYO and LONDON, Dec. 04, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko ...
Fri, 01 Dec 2017
12:13:31 +0000
Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : December 1, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>
Thu, 30 Nov 2017
13:30:00 +0000
Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4
NOVATO, Calif., Nov. 30, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced today that management ...
Wed, 22 Nov 2017
12:35:12 +0000
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Mon, 20 Nov 2017
18:09:44 +0000
ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ultragenyx Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to RARE-US. Comparing the performance and risk of Ultragenyx Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Fri, 17 Nov 2017
22:16:10 +0000
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
Thu, 16 Nov 2017
13:30:00 +0000
Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
NOVATO, Calif., Nov. 16, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed ...
Wed, 15 Nov 2017
18:23:00 +0000
Ultragenyx Announces FDA Approval of MEPSEVII™ (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII
NOVATO, Calif., Nov. 15, 2017-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. ...
Wed, 15 Nov 2017
17:35:57 +0000
U.S. FDA approves Ultragenyx drug for rare enzyme disorder
The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy. The drug is designed to treat patients with mucopolysaccharidosis type VII, or MPS VII, a condition caused by an enzyme deficiency that affects tissue and organs, including the heart, and stunts growth. The drug, Mepsevii, was given to 23 patients who were treated for up to 164 weeks, the FDA said.
Wed, 15 Nov 2017
12:36:26 +0000
Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate
After Heron Therapeutics Inc (NASDAQ: HRTX ), Bristol-Myers Squibb Co (NYSE: BMY ) and Dynavax Technologies Corporation (NASDAQ: DVAX ) found favor with the FDA, it's Ultragenyx Pharmaceutical Inc (NASDAQ: ...
Mon, 13 Nov 2017
12:40:00 +0000
Featured Company News - Deciphera Reported Data Analysis from the Ongoing Phase-1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
Research Desk Line-up: Ultragenyx Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has been a life changer for me. Due to the generosity of a remarkable group of people I quit work at the age of 53 to invest/trade full time. ValueForum is like having a thousand set of eyes watching the markets for you, there is no way an individual working alone could begin to keep up with all the information that as a member of this group you are able to keep up with. Take my right arm but don't take my ValueForum!" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards